Compare Viatris Inc (VTRS) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Walmart Stores Inc — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Walmart Stores Inc trades at $109.88 (market cap $892.90B). The key difference: Walmart Stores Inc is far larger — about 45.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VTRS | WMT | |
|---|---|---|
Market Cap | $19.79B | $892.90B |
Sector | Health | Consumer Staples |
52-Week High | $17.39 | $134.20 |
52-Week Low | $8.74 | $95.67 |
Enterprise Value | $32.00B | $956.35B |
Dividend Yield | 2.83% | 0.88% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Walmart (WMT) trades at $114.24, down 0.62% today, with a neutral technical signal and strong fundamentals including consistent earnings beats and robust cash flow. Revenue reached $681.0B in 2025 (source: company filings, 2025), with net income margin improving to 3.13%. Recent news highlights AI innovation and delivery expansion, while analyst consensus remains bullish with a $142.10 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include competitive pressure from Amazon and margin volatility. Wall Street's strong buy rating (72.72% of analysts) supports upside potential, though investors should monitor execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
